论文部分内容阅读
组织纤维蛋白溶酶原激活剂(Tissue Plasminogen Activator、TPA)是一种静脉给予的溶血拴新药。实验用于心肌梗塞的急救治疗。TPA不是抗原,它只作用在新的血拴形成部位,而无全身性抗凝作用。比静脉注射的链激酶更易使冠状动脉血拴溶解。
Tissue Plasminogen Activator (TPA) is a new drug for intravenous hemolytic tethering. Experiment for emergency treatment of myocardial infarction. TPA is not an antigen, it only acts on the new tethering site without systemic anticoagulation. Coronary artery tethering is easier to dissolve than intravenous streptokinase.